Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Chemotherapy-Induced Cardiotoxicity
NCT07838649Phase 1Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ga-68 Galmydar in Cardiotoxicity, sponsored by Washington University School of Medicine. Primary endpoints: Standardized Uptake Value, Correlation between 68Ga-Galmydar PET and 18F-FDG PET and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Ga-68 Galmydar
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT07838649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07838649.